Hong Kong, 5 November 2026—GENSCRIPT B-1K (HKEX: 01548) reported that its U.S.–listed associate, Legend Biotech Corporation, has filed a Form 6-K with the U.S. Securities and Exchange Commission announcing a broad scientific presence at the 68th American Society of Hematology (ASH) Annual Meeting to be held 12–15 December 2026 in New Orleans.
Key disclosures • Legend Biotech will deliver two oral presentations, two poster presentations and one e-publication featuring CARVYKTI (ciltacabtagene autoleucel) data in multiple myeloma. • Additional pipeline updates include: – A poster on LUCAR-G39D, an anti-CD20/CD19 dual-CAR allogeneic γδ T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. – A poster on LB2501, an in-vivo CD19/CD20 dual-targeting CAR-T therapy in its first-in-human study for the same indication.
Regulatory context The Form 6-K was filed on 4 November 2026 (New York time) after Hong Kong market hours. All statements concerning future development or therapeutic potential are forward-looking and subject to the usual uncertainties outlined in Legend’s risk disclosures.
Board statement The announcement was issued voluntarily by GENSCRIPT B-1K’s Board, chaired by Robin Meng, to keep shareholders informed of material developments at its associate company.
Investors are advised to exercise caution when dealing in GENSCRIPT B-1K’s securities in light of the forward-looking nature of the disclosed information.
Comments